Clinical Data on Dimebon
Reincarnated from its life as an antihistamine in Russia, the drug has several potential activities: It may act by blocking NMDA receptors or voltage-gated Ca2+ channels and by preventing mitochondrial permeability pore transition. Currently marketed drugs are either cholinesterase inhibitors (Aricept, Ortho-McNeil-Janssen Pharmaceuticals’ Razadyne, and Novartis’ Exelon) or MMDA glutamate receptor inhibitors (Forest Laboratories’ Namenda).
Pfizer’s failed trial, called Connection, was part of a seven-study Phase III program to assess Dimebon across all stages of AD and in Huntington disease. The results are in sharp contrast to a Phase II study published in The Lancet in 2008 by researchers from the Alzheimer’s Disease and Memory Disorders Center at Baylor College of Medicine and Georgetown University. They found that Dimebon was safe and well tolerated and that it significantly improved the clinical course of patients studied.
The Baylor trial enrolled roughly 183 AD patients at 11 sites in Russia. Patients received either Dimebon 20 mg three times a day (TID), 60 mg TID, or placebo TID. Other antidementia drugs were not allowed during the study course. The primary endpoint was improvement in cognition.
The Connection trial involved 598 patients with mild-to-moderate AD at 63 sites in North America, Europe, and South America. More than 40% of the patients enrolled were in the U.S. Patients were randomized to one of three treatment groups receiving Dimebon 20 mg TID, 5 mg TID, or placebo TID for six months. No statistically significant improvements for the 20 mg TID group relative to placebo were achieved on the co-primary endpoints of cognition and independently rated global function.
The Phase III failure was not a complete surprise. The Phase II study had its skeptics, among them the director of geriatric psychiatry at New York’s Montefiore Medical Center, Gary J. Kennedy, M.D. Dr. Kennedy, who had said that placebo-treated Alzheimer’s patients in Russia get different care than U.S. patients and must be allowed access to existing treatments. This means that any effect of Dimebon as seen in the Phase II Baylor trial would be an improvement compared to a placebo.